Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus
Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.
You may also be interested in...
Semglee, a follow-on version to Sanofi’s Lantus, finally wins approval more than two months after insulin products transitioned to regulation as biologics; the product is not a biosimilar but can serve as a reference biological for future biosimilar or interchangeable applications from other sponsors.
Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.